Post-ASCO Summary: ctDNA as a patient selection and early efficacy marker in drug development
Fill form to unlock content
Loading, please wait
Error - something went wrong!
Please fill out form to access this item.
Thank you!
Our expert speakers will discuss the latest data from ASCO 2023 and other recent publications and congresses. This will be followed by a panel discussion on the future directions and implications for drug development and clinical trial design in this rapidly evolving space.